Working… Menu
Trial record 1 of 1 for:    CA209-914
Previous Study | Return to List | Next Study

A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03138512
Recruitment Status : Recruiting
First Posted : May 3, 2017
Last Update Posted : August 27, 2019
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 5, 2022
Estimated Study Completion Date : July 7, 2023